Boost for Dr Reddy's, Ambit sets target at Rs 2,761/share
  • WebDesk BTVI
  • Apr 11 2019

Surajit Pal of Prabhudas Liladher discusses advantage for Dr Reddy's over Indivior's woes and shares his view on Cipla which got the EIR from USFDA for a facility in Goa.